Proarrhythmic effects of antiarrhythmic drugs in patients with malignant ventricular arrhythmias evaluated by electrophysiologic testing  by Rae, Alan P. et al.
IKC “0,. 12. No. I 
my 1988:111-P 
131 
ELECTROPHYSIOLOGIC STUDIES ~ 
Proarrhythmic Effects of Antiart- 
With Malignant Ventricular Arrhyt 
Electrophysiologic Testing 
ALAN P. RAE. BSc, MB. MRCP: HAROLD R. KAY, MD. FACC, 
LEONARD N. HOROWITZ. MD, FACC. SCOTT R. SPIELMAN, MD, FACC. 
ALLAN M. GREENSPAN, MD, FACC 
Philudelpkio. Pewtsplvonia 
nmt wrdricular arrbytbmias under&g &ctro*bysioloo_ 
iC stUdb. In 314 pstients with sustained or nonsustainrd 
vordrtculnr tarhycrdtn or veotrtcutar tibrtuntio”, 80, drug 
studii were performed using * standard protomt of pro- 
gnmlwd~lfftri~stim~atian.Thcerb*C: proarrhyth. 
mia were: I) initbdiw of sustained wntricuiar lachy. 
arrhytbmis in P patient in whom only nonsostaincd 
tachycardin was indumd at bwtine: 2) conversion of B 
SW&~ tachycardln that could be termiosted by pr+ 
@aned etectrtcal sttmutattw at baselie to o”e that 
mqhd rardiasersim Iw tetinPtion during drug ther. 
spy: 3) b itiation al P snstabwd tachyarrbythmis by a less 
pggresdve mode ofstbutation than was required at base 
Uoe: and 4) developmeot f spwtaneoos or iocesmnt veo- 
trtcutar Lpchycardfm. 
Proarrbytbmia criterion t occurred uring to ,@%a) of 
I18 stodiff and at teast once in 15 (28%) of 54 patirnts. 
Criterion 1 w~i met during 39 (7%) of 578 studi- and at 
least unre in 29 (13%) * 220 patas. Criterion 3 was 
achieved uring 13.5 (20%) of 681 studies in pntients with 
suntaiined ventrkubw tachyarrhythmias t baseline. Crite 
rion 4 orcurred during 9 (1%) of 8Ot drug studies. 
tow patients in aban we” tot*rrted “e”,riudsr tarby. 
cnrdi was inittated with fewer edrartimuti daring drug 
rludy than at baseline. the drug was cwtioned and the 
pntiants were foltoned op. The recorrence rate of tachy- 
csrdis WBS the same in these patients as in 73 ptknts 
fonmved up 0” regima 0” sbkb the “umber ol extra- 
IdrnYli reqquired for bdtistion “as not reduced. Fwrrhytb. 
mic CfJects of aIdiarrbythmtc regimens are not “nccinrlmn 
during electro@wicb& studies; however, the most fre. 
qwnt type, that is, the reductioo in the number of extra- 
stimuli required to ioitiate arrhythmia, appears to bare 
minimal clinic-at sipittcance. 
adverse feature of most antiarrhythmic drugs (2-E). In addi- 
tion to the development of a new arrhythmia, however, the 
spectrum of proarrhythmiaencompasses worsening of exist- 
ing arrhythmias. This facet is more diicub to identify 
because of the spontaneous variability of arrhythmias and 
their unpredictable nature (9). It has only been since the 
development of improved methods for detec:ing and quan- 
tifying these arrhythmias and the widespread aoplication of 
such techniques that the extent of this adverse feature has 
become apparent (IO). 
The utility of electrophysiologic testing for identifying 
long-term effective antiarrhythmic therapy is well estab- 
lished (I 1-14). More recently. it has been suggested that it 
may also provide a meant of assessing the prowrhythmic 
potential of such therapy, thus preventing the needless 
exposure of patients to possible sudden death due to the 
tolerated dose or the max.;mal dose ollowcd in invesr~gaiional 
protocols. Studies wcrc performed atkr steady ate drug 
levels were obtained. For drug combinations. the same 
dosages were employed as for the individual agents alone. 
except for the combination of amiodarone and intravenous 
procainamide. in which the dose of procoinamidc ws lim- 
ited to l.O+ll mg. 
In trials of a drug regimen at different dose levela. the 
result with the maximal dose was used for subsequent 
analyses. If both parentera, and oral k,orms of the same 
regimen were employed. the result with the oral form was 
used for subsequent analyses. 
Fotlow~up. Follow-up study was performed in patienls 
with inducible sustained tachyarrhythmms to determine 
whether a change in Ihe aggrcsaivcncss of the mode of 
induction influenced the clinical outcome. Patients were 
seen every 3 to 4 months in an awhythmia research clinic. 
All symptomatic episodes compatible with an arrhythmia 
recurrcncc were evaluated by Holler. transtclephonic or 
in-hospital felcmetric monnoring. 
Slstistical analysis. Standard slatislical anzlyres wcrc 
performed. For discrele variables. contingency tables were 
constructed using chi-square or Fisher’s exact tests. For 
continuous variables. an unpaired I test and analysis of 
variance were employed. Mantel-Cox and Breslow statistics 
were used to test the equality of survival curves using 
life-table analysis. The dur&&of follow-up was c~lcuI& 
from the date of electrophysiologic study to the date of 
arrhythmia recurrence or death or the most recent clinic 
visit. Patients whose antiarrhythmic therapy wiu chanced 
during the follow-up period were censored as of the date of 
change of therapy. A p value <O.OS was considered signifi- 
cant. Values arc expressed as mean 2 I SD. 
Results 
Baseline electrop’kysiologic stodies. !n the baseline study 
of 314 prmcnl~ programmed venlricular woulat~on induced 
xntainsd vcnlricular lachycardia m ?10 patients. venuicular 
fibnllauon I” 40 and oonnustained ventricular tachycxdiv m 
54 
Incidence of proarrhythmir etferts (Table 2). The 314 
palicnts underwent a total of 801 drug studies. Overall. a 
proalrhyihmlc ctfcct was observed in 193 (24%) of these 
sludirs. Al least one prowrhythmic effect occurred in I?? 
(39%) of ihe petients. 
Conversion of induced nonswtainad ventricular tarh~car- 
dia to a sustained tachycarrhythmia. The 54 padems wth 
inducib!r nonsustained ventricular khycardia underwenl a 
total of II4 drug studies. Conversion to a sustained arrhyth- 
miaduring dnagtherapy oared in ?Oll8%)ofthese studies. 
In I I cwa. Ihc number of extrastimuli employed was on- 
changed and m 9 cases. induction required fewer extrastimuli. 
77~ r es tuined orrlrylhmirr b~lwed dnring drr,g Brrapy 
was ventricular tachycardia in 18 studies and ventricular 
librittatian in 1. of the 18 episodes of custained ventricular 
tachycardin. Ihe cycle length of the txhycardia during drug 
trezatmeot war increased compared with the baseline cycle 
length in I! epnodes tmeao shanse in cycle length +65 msl. 
In six ep~odes. it was shortened tmean change in cycle 
lengrh -95 m\). This form of proarrhythmraoccurred ai least 
once in IS 1?8%) of 54 patienls. 
Conversion of hemodynamieslly stable ventricular tachy- 
cardia to ventricular tachycardia or rentricular fibrillation 
requiring cwdiovcrsion. Ventricular tachycardia was in- 
duced m the baseline state in 20 parients who subsequsntly 
underwent a total of 578 mdwidual drug studies. Conversion 
of hemodynamically stable ventricular tachycardia to ven- 
tricular tachycardia or ventricular fibrillation requiring car- 
dioversion occurred in 39 (7%) of these studies, and 29 (13%) 
of the patients experienced at least one such event. Ventrk- 
ular fibrillation was induced in 2 patients. and a sustained 
venticular tachycardia was induced in 37. 
During drug rheropy, the induced ventricular tachycardia 
was more rapid in 7 patients (mean change in cycle length 
-78 ms), unchanged in 3 and slower in 27 (mean change in 
cycle length t6l mr). Cardioversion was required in there 
latter 30 patients despite the same or slower rate because of 
more profound symptomatic deterioration associated with 
the tachycardia in 17 patients and increased refractoriness to 
pacing termination with subsequent acceleration of the 
tachycardia in 13. 
Induction of a sustained tachyarrhythmia by a less aggres. 
sive stimulation mode. Because the end point for the stimu- 
lation protoco: employed in our laboratory is the reproduc- 
ible initiation of a sustained lachyarrhythmia, we elected not 
to analyze the change in stimulation mode in patients with 
induced nonsustained iachycardia. 
The 26Opntirnts with u mamined orrltyrhmio underwent 
687 drug studies and in I35 studies (20%). sustained ventrk- 
ular tachycardia was induced by a less aggressive stimola- 
Lion mode than that required for arrhythmia initiation in the 
baseline study. The incidence rate of this type of proarrhyth- 
mia was 23% (130 of 578 studies) for sustained ventrkukr 
tachycardia nd 5% (5 of I09 studies) for ventricular tibril- 
laion. A change in stimulation mode of one fewer extmstim- 
ulus occurred in II8 studies (17%) and a change of two 
extrastimuli occurred in 17 (3%). 
Among the 260 patients, this type of proarrhythmia was 
experienced at least once by 84 patients (34%): 80 (36%) of 
the 220 patients with sustained ventricular tacbycxdia and 4 
(ICI) of the 40 patients with ventricular fibrillation. 
dii. The spontaneous development of sustained ventricular 
tachycsrdia occurred during the administration of anti- 
arrhythmic therapy in 4 (0.5%) of the 801 studies. The 
temporal relation between the onset of the tachycardia nd 
the administration of the drug was such that it could be 
attributed to the agent itself. In five additional studies. 
patients developed incessant ventricular tachycardia aRer 
the initiation of the arrhythmia by programmed stimulation. 
In all nine studies (eight patients), the arrhythmias were 
controlled by drug discontinuation, pacing, cardioversion. 
the administration of other drugs or a combination of these 
ilE%“ES. 
Multiple proarrhythmk effects. Of the 230 patients who 
underwent wo or more drug studies, 48 (21%) experienced a
prowrhythmic event in more than one study. The combina- 
tion of conversion of hemodynamicallv stable ventricular 
tachycardia to ventricular tachycardia br ventricular libril- 
lation requiring cardioversion and reduction in aggressive- 
ness of induction mode occurred in the same drug study in IO 
(2%) of 578 studie. with 9 (4%) of the 220 patients with 
sustained ventricular tachycardia having at least one such 
study. 
Incidence of pmarrhythmia due to individual drug regl. 
nun (Table 3). Because of the small numbers of certain 
drug regimens. only those employed in >I5 studies were 
analyzed separalely. For a single drug regimen, the overall 
incidence rate of proarrhythmia was 23% (range IS to 37%) 
and for combination regimens the rate was 29% (range 22 to 
30%). There was no significant difference between the inci- 
dence of proarrhythmia in single and combination regimens. 
Qninidine resskd in the loarr~ iwidenre wm OJ 
proarrhylhmin C/S%): this was significantly lower than the 
rate associated with amiodarone (p < 0.01). tlecainide ip < 
0.05). indecainide Ip < 0.05) and the combinations of 
quinidioe plus mexiletine (p C 0.051 and amiodamne plus 
&ocsina&de (p < 0.05). &c&amide also resulted in B 
significantly lower incidence of proarrhythmia than did 
amiodarone (p < 0.01). Although the type IC agents Aecai- 
nide and indecainide were associated with the highest inci- 
dence rates of proarrhythmia when used as a single regimen 
03 and 37%, respectivvelvl, these rate3 were not atistically 
difkent from those of other single regimens except that of 
quinidine. No combination regimen was associated with 
significantly more proarrhythmia than that of other combi- 
nation regimens. 
When the incidence of proanhythmia was reanalyzed 
excluding the third criterion (that is. change in number of 
extrastimuli). proarrhythmia was more common during stud- 
ies with Recainide than in those using qumidine or procaina- 
mide (p < 0.05). 
In 40 patients who had a proarrhythmic event during 
w&tat& ofa single drug, that agent was subsequently used 
in a combination regimen. Eighteen (45%) of these 40 
patients had another proarrhythmic event during that com- 
bination regimen, whereas the remaining 22 patients (5S%) 
had no prowrhythmic event during the combination therapy. 
In three of the latter patients, each campaxnt of the 
combination regimen had resulted in proarrhythmia when it 
was administered individually. 
There was no significant difference between the swan 
drug concentrations in studies with and without a proarrhyth- 
tic event, except in the case of quinidinc. which had d 
significantly higher level in studies resulting in proarrhyth- 
mia (3.8 2 1.4 versus 2.9 * I.0 &ml. respectively: p < 
O.Ot). although this value was still within the usual range for 
our Idboratory (2 to 5 w/ml) (Table 4!. 
Surfare el&cn&&phie intervals (Table 5). The sur- 
face electrocardioeraohic (ECG) intervals ORS. OTC and 
.tTc were analyzed~There &a no rignificant kr&e;n the 
interwls measured as the absolute value or as Percent 
change between drug studies that were and were not asso- 
ciated with proarrhythmia. When these interval changes 
were analyzed in groups of the various forms of pmarrhyth- 
mia. the only significant difference was noted in drug studies 
in which a hemodynamically stable ventricular tachycardia 
was convened to ventricular tachycardia requiring cardio- 
version: in these studies Ihe JTc interval (both absolute and 
as a percentageI was shorter. No significant differences were 
Table 4. Drue Lack in Padems With and Without Proarrhythmia 
observed when these interval changes were analyzed for 
individual drues. 
Baseline demographic characteristics of patients with 
oruarrhvthmia (Table 6). The onlv variables that differed 
between patients who djd and did not manifest proarrhyth- 
mia were left ventricular ejection fractiou and QT interval, 
although the latter WBS still within normal limits in patients 
with a prowrhythmic event. When the anaiysis of demo- 
graphic factors was performed for patients who had 
proarrhythmic responses dcfincd by criterion I, 2 or 4 
(excluding patients in whom the only manifestation of 
proarrhythmia was a change in the number of extrastimuli 
required for initiation of arrhythmia). the ejection fraction 
remained significantly lower in patients with than in those 
without proarrhythmia. There was no difference in the 
incidence of proarrhythmia in patients with different types of 
underlying heart disease. 
Fallow-up. Although patients were not discharged on an 
antiarrhythmic drug regimen that produced either conver- 
sion of nonsustained ventricular tachycardia to a sustained 
arrhythmia or conversion of hemodynaniically stable ven- 
tricular tachgcardia to a ruslained arrhythmia requiring 
cardioversmn, long-term follow-up was available for 40 
patients in whom fewer extrastimuli wcrc required for 
arrhythmia induction during drug therapy. These 4tt patients 
were compared with 73 patients who continued to have 
inducible sustained arrhythmias requiring the same or a 
greater number of extrastimuli for initiation. Over a mean 
follow-up period of I7 + I4 months (range 2 days to 52 
monthsl. there were I3 nonfatal arrhythmia recurrences and 
9 sudden deaths (55% talal recuwence rate) in the 40 patients 
in whom fewer ettrNimuli were required for arrhythmia 
induction. In 73 patients in whom the same or one or two 
more extrastimuli were required to initiate the arrhythmia. 
there were I6 nonfatal arrhythmia recurrences and I9 sud- 
den deaths (48% tolal recunence rate). There were three 
nunsudden cardiac deaths, one in the former group and two 
in the Idler. Life-table analysis demonrwued no significant 
ditTerence between these two groups. 
Of interest. in five patients discharged on a regimen in 
which their arrhythmias were induced by two fewer extra- 
stimuli, two arrhythmia recurrences and two sudden deaths 
occurred. 
Discussion 
Prosrrbytbmin. Recognition of the malignanl polential of 
ventricular arrhylhmias has led to the incrcascd prescription 
ofanliarrhythmic drugs and the development of newer. more 
potent ageets (U-17). Despite their undoubted efficacy. 
these drugs may also worsen the arrhythmias they were 
inlended to suppress (IR.19). an action that tends lo be 
unpredictable and in most caw occurs without premorhid 
warning signs. 
In a study using Halter monitoring techniques. Velebit el 
al. (IO) observed un incidence of proarrhythmiaaf I I% in 80 
patients undergoing 722 drug studies. Because of the known 
variability in the frequency of ambient ventricular ectopic 
activity. Ihe critel-ion for proarrhythmia in that study was I) 
a Cfold increase in the hourly frequency of ventricular 
ectopic rhythms, 2) a t&fold increase in rcpclhivc forms 
compared with baseline. or 31 the first occurrence of IUS- 
tained ventricular tachycardia. Overall. 34% of patients 
experienced at least one proarrhythmic event during drug 
evaluation. 
The applicability of electrophvsioloeic testing to identifv 
drug-indiced pro&hythmia ias sug&tcd in-a study b; 
Ruskin el al. (201. Among six patients who had had an out of 
huspital cardiac arrest, no ventricular tachyarrhythmia could 
be induced in the baseline study. but in four of the six. 
ventricular tachycardia was inducible when they were given tachycardia m a repeat baseline study required the same or 
the nntiarrhythmic medication they had been taking at fPe an additmnal number of extrastimuli in 85% of patients. 
time of the spontaneous clinical event. fhus. m 8s many as IS% ofpatients. the arrhythmia can be 
Types of pmarrhythmie responses. There are as yet no / Induced by fewer extrastimuli simply because of spontane- 
standardized criteria to define a proarrhythmic response ous variation. This observation lessens the impact of the 
during electmphysiologic testing. The overall incidcncc 20% incidence rate of this phenomenon observed in our 
rates reported in previous studies (21.22) of 13 and 16% are pattexs. Of note, the stimulation end point in the study by 
lower than the 24% incidence rate observed in our study. McPhenon et al. (28) was the induction of nansustained 
These differences relate to the definitions of proarrhythmia ventricular tachycardia in contrast o a sustained arrhythmin 
employed in these studies, in addition to the recognized end pomt (as employed in this study). The tatter end point 
differences in the methodology of electrophysaologic testing may iead to an overestimation of the incidence of cases 
which hamper any interstudy comparison of this procedure. rcquirine fewer extrastimuli, esueciallv in mtients with a 
In the former studier. although up to three extrastimuli were su&ined arrhythmia at baseline. Others (ie3t) have re- 
used. the end point of the stimulation protocol was the ported similar data. indicating that. although the overall 
induction of nonsustained ventricular tachycwdia in contrast reprodwbdity of ventricular tachycardia induction is goud. 
to the sustained arrhythmia end point required in the stimu- substantial dav to dav variabilitv in the number ofextrastim- 
lation protocol in the present study. uli required fdr indu&on does;xi$t. 
These interstudy differences also apply to the comparison Follow-up of pptteots e)n tmtontiatty proarrhythmte regt- 
of the incidence for individual types of pmarrhylhmic re- mens. During follow-up study. there was no significant 
sponse. The incidence rate of conversion of nonsustained difference between patients on a regimen considered to he 
ventricular tachycardia to a susbined arrhythmia has previ- potentially proarrhythmic (change in initiation made--“less 
ously been reported (21.23) as rangjog f:om 4 to 13%. The wessive”l. and patients on a regimen that was not con- 
higher incidence rate of 16% in the present study is presum- sidered proarrhythmic. This is an impOrtant observation 
ably related to the differences in the sttmulation end Doints 
em&yed. 
suggesting that the reduction in the initiating mode by one 
extrastimulus is not of sufficient predictive value to he used 
Swemlfacrors may account for rhe conversion of hem- m clinlcal practice. This was previously sumested by Poser 
dynamically stable rochycordio IO rachycnrdio reqairing et al. (22) -who caieguiad this effect &definite agravb 
cardioversion. In the study by Tomes et al. (21~. this lion defined a! induction by two fewer extrastimuli and 
proarrhythmic effect noted in 2% of cases was due to possible ag_Sravatian when only one less extrastimulus w.,s 
accelerationofthe inducedarrhythaia. In the present study. required. In be present study, only 3% of drug studies 
we included not only acceleration of the arrhythmia (?%I. would be classified as definite aggravation (induction by two 
hut also symptomatic deterioration in response to the tachy- ?ewer extmstirnuti), and four of five patients discharged on 
cardia (3%) and resistance to pacing termination wiiir ruh- ach a regimen experienced a sudden death or arrhythmia 
sequent acceleration (2%). ~wrrence during follow-up study. This suggests that a 
A worsmning of symp!oms des;“e n rloeer rnckycordio reduction by two extrastimuli may be a more specific end 
may reflect the impact of the antiarrhythmic agent on myo- point. Further wbrtantiation for this concept is provided by 
cardial perforttmnce because most agents exhibit negative the work of Cooper et al. (30). who showed that when the 
inotropism. especially in the presence of pre-existing left definition of proanhythmia is adjusted for the &drug vari- 
ventricular dysfunction (24-27). Whether this should be ability in the number of extrastimuli required for arrhythmia 
considered spcitically a proarrhythmic effect or an addi- induction. a reduction in the number of extrastimuli pre- 
tional adverse feature is debatable. Conversely, although dicted a worse prognosis. In their study. patients followed 
resislance to pacing termination is a recognized proarrhyth- up on a regimen that produced a significant reduction in the 
mic effect, it can he argued that it does not have an iqwt on number of extrastimuli had a recurrence rate of 82% com- 
the spontaneous initiation of the arrhythmia, which is the pared with 33% in other patients. 
important end paint for this technique to idcm;fy. Incidence of pnwrbythmin. Although we have rcponed 
A reducrioa in Ike nwnber of extrastimuli requited for an overall incidence rate of proarrhythmia of 24% in drug 
arrhythmia inducrion occurred$ar mom Jiequmdy lhaa did studies. we employed broad-based efinitions for a number 
other lyprs cf proorrkyrhmic response in the presmr audy. of different pmarrhythmic responses that have been sug- 
The overall incidence rate of Zoo/a contrasts with the 6 to 8% gested in previous studies. The incidence rate of proarrhyth- 
previously reported (21.22). It must be emphasized that this mia in this study was 8% if the results are analyzed using the 
form of arrhythmia induction is very dependent on repro- rnwe rigorous and specific criteria of I) conversion of 
ducibility of arrhythmia induction. Reproducibility of elec- nonsummed ventricular tachycardia to a sustained arrhyth- 
trophysiotogic testing has been evaluated by McPherson et mia; 2) conversion of hemcdynawically stable ventricular 
al. (281. who demonstrated that the induction of ventricular tachycardia to ventricular tachyca dia requiring cardiover- 
sion because of acceleration of the induced arrhvfhmia: 3) 
reduction by two extrastimuli of the number required for 
arrhythmia induction: and 4) sponmneous development of 
ventricular tachvcardia. 
Proerrhythnk in relatlon to ittdividunl drug regimens. 
The frequency of proarrhythmia in relation to individual 
antialrhylhmic agents reported in previous studies (10,21,22) 
has ranged from 6 to 36%, which is comparable with the 15 
to 37% in this present study. However, in contrast to these 
previous studies in which there was no significant difference 
in the incidence for any drug, we havehemonstrated that 
quinidine R~S significantly less proarrhythmic than several 
other single and combination regimens. In adtition, procai- 
nzmide VJBS less proarrbythmic tbsn akodarone. Although 
these ditferences may reflect the different study methodolo- 
gies, the present study is the largest reported and thus may 
reduce the possibility of error caused by the sampling of 
small numbers. Of interest, the type IC agents caused the 
highest incidence of proarrhythmia. Although this has been 
noted previously (22). other repons (10.32) have not con- 
firmed these observations. 
As in the determination of the incidence of proarrhythmic 
responses. the criteria employed for these responses are 
extremely important when analyzing the incidence in rela- 
tion to individual drug regimens. When the results were 
reanalyzed only for conversion of nonsustained ventricular 
tachycardia to a sustained arrhythmia and conversion of 
hemodynamically stable ventricular tachycardia to a sus- 
tained arrhythmia requiring cardioversion, Recainide was 
found to have significantly more proarrhythmia than either 
quinidine or procainamide (p < 0.05). 
An imporiuntfeatm of drug-reloied proorrhyfhmia is its 
a@xmw rrnpredictobilify. The development of proarrhyth- 
mia was not related to the attainment of toxic levels of the 
drug and although. with quinidine, the serum level was 
higher in the studies with proarrhythmia. it was still within 
the accepted therapeutic range. Similarly, there were no 
specific changes in surface ECG intervals. in particular the 
QTT, interval, that were of predictive value. In addition, 
there was no evidence that proarrhythmia with one drug 
predicted proarrhythmia development with another agent, 
even if the agents had similar electmphysiologic etiects. 
There have been no previous mtblished reoorts on the 
incidence of proarrhythkia c&d by combktion drug 
regimens. The incidence with the combinations analyzed 
was not significantly different from that of single drug 
regimens, and there was no correlation between the devel- 
opment of prwarrhythmia due to one agent in the combina- 
tion and subsequent development of proarrhythmia with the 
combination. This suggests that a proarrhythmic effect seen 
with a single agent does not preclude its use in a combination 
drug regimen. 
Mechanisms of proarrhythmia. The electrophysiologic 
basis for most recurrent arrhythmias is reentry, and for the 
initiation ofa ,:entrant tachycardia, a balance in conduction 
and refractoriness d the two limbs of the circuit is required. 
Antiarrhythmic agents can prevent or terminate an a-rhyth- 
mia by their varying effect on conduction and refractoriness: 
however, these same effects can provide sufficient perturha- 
tion of the circuit to initiate and maintain att arrhythmia. The 
slowing of conduction in one limb of a circuit can permit the 
delay necessary in distal tissue to recover excitability and 
thus sustain a previously nonsustained arrhythmia. Acceler- 
ation of an arrhythmia may occur because of an increase in 
the conduction velocity of a tachycardia wave front. Fur- 
thermore, variability of antiarrhythmic action in different 
areas of the myocardium may potentiate or suppress dif- 
ferent potential reentrant circuits. 
Proarrhythmic response were more common in patients 
with a lower left ventricrrlar &ction fraction, and this may 
indicate a relation to more diffuse disease. In such a situa- 
tion. greater inhomogeneity ofconduction and refractoriness 
might be anticipated and the adverse e5ects of the attti- 
arrhythmic agents expected. The longer QT interval in this 
group may also be causally related because one would 
expect a greater inhomogeneity in this group as well. 
Conclusionr. Drug-related proarrhythmia is a potentially 
lethal adverse feature of all antiarrhythtrtic therapy. There 
are no predictive variables that enable the physician to 
anticipate the development of such a response and, there- 
fore, guide the selection of antiarrhythmic therapy. This 
study demonstrates that worsening of arrhythmias by drug 
therapy can be identified in a significant proportion of 
patients. Various criteria for proarrhythmic responses have 
been analyzed. and the incidence is dependenl on the 
definitions employed. The validity of certain criteria have 
yet to be determined. We suggest that this aspect may 
extend the already established utility of electmphysiologic 
testing in the management of patients with ventricular 
tachyarrhythmias. 

